Navigation Links
Isis Pharmaceuticals To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/7/2012

CARLSBAD, Calif., Nov. 07, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 2:00 p.m. ET in New York, NY. 

A live audio webcast of the presentation and panel will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, in the United States and Europe following regulatory approval.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
2. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
4. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
5. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
6. AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. Thom Rowland Joins Arbor Pharmaceuticals as Vice President of Commercial Operations
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
9. Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
10. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... TIJUANA, Mexico , Dec. 24, 2014 /PRNewswire/ ... treatment of its first patient in its study ... to the American Stroke Association, ischemic strokes account ... continues to enroll qualified patients in the study, ... Intravenous Administration of Allogeneic Mesenchymal Stem Cells and ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... , December 24, 2014 ... at an average rate of 8.1%. The US has ... knee and spine surgeries are the common orthopedic procedures ... have a lower penetration. Increased number of product recalls ... Non-metallic orthopedic devices have gained popularity in the industry ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... , STAMFORD, Conn. , Feb. ... treatment will soon have advanced technology available to the medical ... FUJIFILM Medical Systems USA (Fujifilm), and AmeriCares, a portable digital ... and will be sent to a hospital where currently x-ray ...
... , , SINGAPORE , UPPSALA, Sweden ... Novus Scientific Pte. Ltd today announced that the US Food and ... the TIGR™ Matrix Surgical Mesh, for use in reinforcement ... Mesh is a 100 percent resorbable, synthetic matrix, knitted from two ...
Cached Medicine Technology:Local Organizations Partner to Improve Healthcare in Haiti 2Local Organizations Partner to Improve Healthcare in Haiti 3Local Organizations Partner to Improve Healthcare in Haiti 4Local Organizations Partner to Improve Healthcare in Haiti 5Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... 25, 2014 AngelWeddingDress.com tries its best ... online realm. Today, the business has introduced its new ... prom dress promotion. , The new prom outfits are ... every dress lover. They are specially designed for 2015. ... dresses should visit its website before Jan. 26, ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... 24, 2014 Connie Casad, MD, a ... medicine advocate with 30 years of practice experience in ... the health benefits of dietary detoxification. The second study ... following excellent results from test patients who just completed ... explain her interest in conducting the study, Dr. Casad ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... exercise improves your cholesterol profile, even in the absence ... how exercise affects the level of 'good' and 'bad' ... body attached to protein molecules, the combination being known ... or 'bad' cholesterol) are linked to heart disease, while ...
... person aged 40 or over has a lifetime risk of ... they have high blood pressure. Heart failure is an increasing ... within the heart which makes it hard to pump blood ... the condition is very disabling. ,Researchers for the ...
... gets better if specialists in critical care medicine manage ... have analysed the evidence on managing patients in intensive ... much better if they are cared for by a ... ,Previous research has suggested that the involvement ...
... do not fare as well as men when it comes ... Germany now confirm what has long been suspected - kidneys, ... be rejected// by the recipients than those from males. Female ... ,The study covered more than 114,000 kidney transplants, ...
... and vegetables which increases by one third for every additional ... and content of people's daily diet.//According to a new study ... these is the convenience of shopping facilities. The survey looked ... ,Six times more supermarkets were located in areas ...
... test for bowel cancer based upon a molecule found only ... highly curable if caught early. Screening with sigmoidoscopy - an ... the disease. Now researchers in the find that a reliable ... ,The bowel sheds cells into feces all the time. ...
Cached Medicine News:
... The Diamedix Immunosimplicity (Is) Rubella IgG ... for the qualitative and quantitative detection ... can be performed either manually or ... EIA Processor. The results are reported ...
... VITROS HBsAg assay is the ... the U.S. Food and Drug,Administration ... a random,access format on the ... Now you can run an,HBsAg ...
... For use as a quality ... immunoglobulin M (IgM) antibodies to ... IgM), IgM antibodies to hepatitis ... B e antigen (HBeAg) and ...
... This SIGNET anti-PSA antibody gives ... all cases of benign hyperplasia. In ... intense staining and 34% give definite ... only a minority of cells; this ...
Medicine Products: